Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription


13.03.2023

1 AJR Am J Roentgenol
1 BJU Int
1 BMC Cancer
1 BMC Urol
1 Cancer Res
1 Eur Radiol
4 Eur Urol
1 Hum Pathol
1 Int J Radiat Oncol Biol Phys
2 J Nucl Med
1 J Urol
1 Lancet Oncol
1 Magn Reson Imaging
2 Nat Rev Urol
2 Oncogene
2 Oncol Rep
3 PLoS One
1 Proc Natl Acad Sci U S A
3 Prostate
1 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. SEYFRIED N, Mahran A, Panda A, Obmann VC, et al
    Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy.
    AJR Am J Roentgenol. 2021;217:908-918.
    PubMed         Abstract available


    BJU Int

  2. YAXLEY JW
    Focal irreversible electroporation for treatment of primary and radio-recurrent prostate cancer - the evidence is mounting!
    BJU Int. 2023 Mar 6. doi: 10.1111/bju.15987.
    PubMed        


    BMC Cancer

  3. KAWAHARA T, Saigusa Y, Yoneyama S, Kato M, et al
    Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide.
    BMC Cancer. 2023;23:214.
    PubMed         Abstract available


    BMC Urol

  4. YOSHIDA S, Takahara T, Arita Y, Ito M, et al
    A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).
    BMC Urol. 2023;23:33.
    PubMed         Abstract available


    Cancer Res

  5. LI M, Liu M, Han W, Wang Z, et al
    LSD1 inhibition disrupts super-enhancer driven oncogenic transcriptional programs in castration-resistant prostate cancer.
    Cancer Res. 2023 Mar 6:CAN-22-2433. doi: 10.1158/0008-5472.CAN-22-2433.
    PubMed         Abstract available


    Eur Radiol

  6. BAUCKNEHT M, Miceli A, Signori A, Albano D, et al
    Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study.
    Eur Radiol. 2023 Mar 9. doi: 10.1007/s00330-023-09516.
    PubMed         Abstract available


    Eur Urol

  7. ROY S, Sun Y, Morgan SC, Wallis CJD, et al
    Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial.
    Eur Urol. 2023 Mar 7:S0302-2838(23)02626-X. doi: 10.1016/j.eururo.2023.
    PubMed         Abstract available

  8. CHEN F, Madduri RK, Rodriguez AA, Darst BF, et al
    Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.
    Eur Urol. 2023 Feb 27:S0302-2838(23)02561-7. doi: 10.1016/j.eururo.2023.
    PubMed         Abstract available

  9. HABUCHI T
    Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study.
    Eur Urol. 2023 Mar 2:S0302-2838(23)02630-1. doi: 10.1016/j.eururo.2023.
    PubMed        

  10. SHEE K, Cowan JE, Balakrishnan A, Escobar D, et al
    Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort.
    Eur Urol. 2023 Mar 2:S0302-2838(23)02622-2. doi: 10.1016/j.eururo.2023.
    PubMed         Abstract available


    Hum Pathol

  11. ABDULFATAH E, Fine SW, Lotan TL, Mehra R, et al
    Reprint of: de novo neuroendocrine features in prostate cancer.
    Hum Pathol. 2023 Mar 7:S0046-8177(23)00037-0. doi: 10.1016/j.humpath.2023.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  12. HOULIHAN OA, Redmond K, Fairmichael C, Lyons CA, et al
    A Randomised Feasibility Trial of Stereotactic Prostate Radiotherapy with or without Elective Nodal Irradiation in High-Risk Localised Prostate Cancer (SPORT Trial).
    Int J Radiat Oncol Biol Phys. 2023 Mar 7:S0360-3016(23)00217.
    PubMed         Abstract available


    J Nucl Med

  13. RAVI P, Whelpley B, Kelly E, Wolanski A, et al
    Clinical Implementation of (177)Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.
    J Nucl Med. 2023;64:349-350.
    PubMed        

  14. JOHN N, Pathmanandavel S, Crumbaker M, Counter W, et al
    (177)Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
    J Nucl Med. 2022 Sep 8. pii: jnumed.122.264677. doi: 10.2967/jnumed.122.264677.
    PubMed         Abstract available


    J Urol


  15. Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
    J Urol. 2023;209:815.
    PubMed        


    Lancet Oncol

  16. FURLOW B
    US lawmakers call on Biden Administration to lower the price of enzalutamide.
    Lancet Oncol. 2023;24:206.
    PubMed        


    Magn Reson Imaging

  17. SONG E, Long J, Ma G, Liu H, et al
    Prostate lesion segmentation based on a 3D end-to-end convolution neural network with deep multi-scale attention.
    Magn Reson Imaging. 2023;99:98-109.
    PubMed         Abstract available


    Nat Rev Urol

  18. STONE L
    Immunoproteasome inhibition in CRPC.
    Nat Rev Urol. 2023;20:130.
    PubMed        

  19. RASTOGI I, Muralidhar A, McNeel DG
    Vaccines as treatments for prostate cancer.
    Nat Rev Urol. 2023 Mar 6:1-16. doi: 10.1038/s41585-023-00739.
    PubMed         Abstract available


    Oncogene

  20. NIKESITCH N, Beraldi E, Zhang F, Adomat H, et al
    Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling.
    Oncogene. 2023;42:748-758.
    PubMed         Abstract available

  21. YENDE AS, Williams EC, Pletcher A, Helfand A, et al
    TRIM28 promotes luminal cell plasticity in a mouse model of prostate cancer.
    Oncogene. 2023 Mar 8. doi: 10.1038/s41388-023-02655.
    PubMed         Abstract available


    Oncol Rep

  22. JI J, Shen T, Li Y, Liu Y, et al
    CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
    Oncol Rep. 2021;45:921-932.
    PubMed         Abstract available

  23. ZHU J, Qin P, Cao C, Dai G, et al
    Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
    Oncol Rep. 2021;45:963-974.
    PubMed         Abstract available


    PLoS One

  24. DERIS A, Sohrabi-Haghighat M
    Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics.
    PLoS One. 2023;18:e0282646.
    PubMed         Abstract available

  25. VIDAL I, Zheng Q, Hicks JL, Chen J, et al
    GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States.
    PLoS One. 2021;16:e0241934.
    PubMed         Abstract available

  26. SYVERSEN IF, Elschot M, Sandsmark E, Bertilsson H, et al
    Exploring the diagnostic potential of adding T2 dependence in diffusion-weighted MR imaging of the prostate.
    PLoS One. 2021;16:e0252387.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  27. WU WF, Wang L, Spetsieris N, Boukovala M, et al
    Estrogen receptor beta and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.
    Proc Natl Acad Sci U S A. 2021;118:e2011269118.
    PubMed         Abstract available


    Prostate

  28. TAN YG, Law YM, Ngo NT, Khor LY, et al
    Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy-monitored study.
    Prostate. 2023 Mar 9. doi: 10.1002/pros.24517.
    PubMed         Abstract available

  29. CHAMORRO CASTILLO L, Garcia Morales L, Ruiz Lopez D, Salguero Segura J, et al
    The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice.
    Prostate. 2023 Mar 9. doi: 10.1002/pros.24515.
    PubMed         Abstract available

  30. CONOVER MM, Weaver J, Fan B, Leitz G, et al
    Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data.
    Prostate. 2023 Mar 6. doi: 10.1002/pros.24510.
    PubMed         Abstract available


    Urology

  31. REZAEE ME, Li H, Pienta KJ
    An Enhancing Renal Mass in Metastatic Prostate Cancer.
    Urology. 2023 Mar 7:S0090-4295(23)00203-0. doi: 10.1016/j.urology.2023.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: